To date, gene therapies for human application rely on engineered promoters that cannot be finely controlled. Here, we report a universal switch element that allows precise control for gene silencing or gene replacement after exposure to a small molecule. Importantly, these small molecule inducers are in human use, are orally bioavailable when given to animals or humans, and can reach both peripheral tissues and the brain.
Introduction
While viral and nonviral approaches for gene therapies have made tremendous advancements over the last twenty years, the major focus has been on the cargo delivery system; e.g., viral capsid evolution and engineering for adenoassociated viruses (AAVs), expanding the landscape of cell-targeting envelopes for lentiviruses, and refining lipid nanoparticles for improved uptake. However, the cargo itself, and more importantly the elements controlling the expression from that cargo, have been largely untouched aside from using engineered promoters or 3' regulatory elements to restrict expression to certain cell types 1,2 .
To address this gap, we developed X on , a method to finely control protein expression via a drug inducible switch. Importantly, X on does not require any bacterial or other external elements for regulation. The X on system can be applied to any genetic element of interest in cells or animals, and takes advantage of drugs that are orally bioavailable and in human use.
Results
Initial experiments to test our approach were done using the actual target of the drugs, the SMN2 gene, for Spinal Muscular Atrophy (SMA) therapy. SMA is due to mutations in the gene SMN1. Humans have a very similar gene, SMN2 that can serve to modify the severity of SMN1 deficiency depending on the number of SMN2 copies resident in the patient's genome. SMN2 cannot fully replace SMN1, however, because unlike SMN1, SMN2 has undergone variations impairing exon7 inclusion. As a consequence, only ~10% of SMN2 is correctly spliced 3, 4 . Two drugs, LMI070 5 and RG7800/RG7619 6 , can improve exon7 inclusion and are in later stage clinical testing. We reasoned that the exon6/7/8 cassette could be co-opted and refined to control the expression of a gene of interest, rather than SMN2 protein.
For this, SMN2-on cassettes were generated to provide drug-induced reporter gene expression. HEK293 cells were transfected with the SMN2-on expression cassettes and luciferase activity evaluated in response to varying doses of LMI070 or RG7800. As depicted in Fig 1a, firefly luciferase activity would be expected with exon 7 inclusion, while exon 7 exclusion results in the presence of a premature stop codon and lack of signal. The SMN2-on switch was tested in its native format, or altered for constitutive inclusion or reduced background exon 7 inclusion by modifying SMN2 exon 7 donor or acceptor splice sites, respectively ( Fig. 1b-c) . Both RG7800 and LMI070 induced luciferase activity from the SMN2-on minigene, with a complete splicing switch evident at drug concentrations greater than 1 µM (Fig. 1c , Extended Data Fig. 1a,b) and an overall induction of approximately 20-fold for the refined SMN2-on switch system ( Fig   1d ,e, Extended Data Fig. 1c ). In the setting of the SMN2-on cassette, LMI070 was more active than RG7800 (Fig 1d, Extended Data Fig. 1a ,b), which may be due to their different mechanisms of action 7, 8 .
We next set out to test for exons that were more sensitive to LMI070 to reduce nontarget splice events. We treated HEK293 cells with 25 nM LMI070 for 12 hours and ascertained the splicing changes induced using RNA-Seq. Reads obtained from 4 control and 4 LMI070 treated samples were aligned to the genome using the STAR aligner 9 and splicing events exclusive to the LMI070 treated samples identified ( Fig. 2a , Extended Data Table 1 , Extended Data Fig. 2 a-h). A total of 45 novel splicing events were identified following LMI070 treatment that were above our threshold of an average of greater than 5 novel intron splicing events in LMI070 treated samples ( Fig. 1 , Extended Data Table 1 ). Among them, 23 events were found exclusively and in all LMI070 treated samples, and the remaining 22 were evident in all treated and in one of the control untreated samples (Extended Data Table 1 ). To assess exclusivity of the 45 identified candidate positions to LMI070 treatment the chromosomal locations were assessed in Intropolis 10 , a resource containing a list of all exon-exon junctions found in 21,504 human RNA-Seq datasets. In one example, the canonical exon-exon junction in SF3B3 ( Fig. 2b ; Extended Data Table 1 ) was observed in 12,872 datasets at an average frequency of 64 counts per dataset, while the LMI070 induced splice event was observed in 10 and 1 dataset(s), respectively, for the 5' and 3' exon-exon junctions.
The average counts per dataset for the 5' exon-exon junction was 1.3 while the 3' exonexon junction was observed only once in all 21,504 sets (Extended Data Table 1 ).
The pseudoexons identified in LMI070 treated samples share a strong 3' AGAGUA motif consistent with the previously identified U1 RNA binding site targeted by LMI070 ( Fig. 2c ) 5 . To experimentally validate the identified LMI070 induced splicing events, primer pairs binding the flanking exons of the top 5 candidate genes ( Fig.2a , Extended Data Fig. 2a -e) were generated. Robust amplification of the novel exons was detected by PCR exclusively on cDNA samples generated from HEK293 cells treated with LMI070 ( Fig. 2d ). We evaluated the impact of LMI070 treatment on global gene expression by assessing differential expression analysis. DESeq2 revealed strikingly few differentially expressed genes with only 6 upregulated and 24 downregulated genes passing our threshold for significance (p< 0.05; Benjamin-Hochberg multiple testing correction) 11 . After filtering out genes with low fold-change values (<0.1 fold) only 5 upregulated and 9 downregulated genes were identified ( Fig. 2e ).
We next developed a series of switch-on cassettes from the top 4 LMI070-responsive exons found in our RNA-Seq dataset. For this, the minimal intronic intervening sequences necessary to recapitulate splicing of pseudoexons in SF3B3, BENC1, C12orf4 and PDXDC2 were cloned upstream of luciferase or eGFP cDNAs ( Fig. 3a ,c).
To limit translation only in response to the drug, a Kozak sequence followed by an AUG start codon were positioned within the novel exon to be included in response to LMI070 binding ( Fig. 3a,c) . HEK293 cells were transfected with the candidate cassettes, treated with LMI070, and luciferase activity or eGFP expression determined 24h later.
Increased luciferase expression was observed for each candidate cassette in response to LMI070, with the SF3B3-on switch showing a more than 100-fold induction (Fig 3b) .
Notably, this is 5x the 20-fold induction afforded by the SMN2-on cassette (Fig 1e) .
Similarly, eGFP expression was only detected in cells transfected with the SF3B3-on-eGFP cassette in response to LMI070 treatment (Fig 3d) .
While there was measurable baseline luciferase activity in the absence of LMI070 for all candidate cassettes, the SF3B3 cassette had the least background (Extended Data Fig   3a) . As recent work using ribosome foot printing revealed that non-AUG start codons provide for translation initiation 12 , we evaluated the presence of in frame non-AUG start codons that could drive luciferase translation in the absence of drug. We found that all cassettes contained in frame non-AUG codons, however there was only one in frame non-AUG codon in the SF3B3 cassette (Extended Data Fig 3b) .
To assess the baseline splicing from the engineered switch cassettes two different PCR assays were done, one with primers binding the flanking exons to detect all transcripts, and another with a primer binding within the novel spliced exon (Extended Data Fig 3c) .
The LMI070-spliced exon was not detected with primer pairs binding the flanking exons, whereas there was faint signal when priming specifically the novel exon sequence (Extended Data Fig 3c) . Overall, our results suggest that in the absence of LMI070 the alternative exon may be included in a small fraction of the transcripts, mirroring what was found in the Intropolis dataset (Extended Data Table 1 ).
Splicing machinery selection of 5' and 3' splice sites pairs is defined by several cisacting sequences that collectively comprise the 'splicing code', including combinations of silencer and enhancer splicing sequences that repress or promote the selection of cryptic or correct splice sites. Using the Human Splicing Finder website 13 , we screened the SF3B3 intron sequence for putative silencer and enhancer sequences that could modulate inclusion of the SF3B3 LMI070-spliced pseudoexon (Extended Data Fig 3d) .
Three intronic regions rich in silencing sequences that could repress splicing in the absence of the drug were identified downstream of the pseudoexon. To test their impact on drug-induced control, SF3B3-on-reporter cassettes containing the full intron sequence (SF3B3int), intron fragments rich in silencer sequences (SF3B3i1, SF3B3i2, and SF3B3i3), or an intron fragment less enriched for intronic silencer sequences (SF3B3i4) were generated (Extended Data Fig 3e) . HEK293 cells were transfected with the original SF3B3-on switch or the cassettes containing alternate intronic sequences and splicing and luciferase activity determined 24h later. Whereas cells transfected with SF3B3i4 showed activity similar to the original SF3B3-on construct, luciferase activity was reduced in all the other groups irrespective of drug treatment (Extended Data Fig   3f,g) . The fold-change in luciferase activity in response to LMI070 was significantly higher in cells transfected with plasmids containing the original intron (>200 fold, Extended Data Fig 3g) . Surprisingly, the reduction of the luciferase activity was not related to splicing repression of the novel exon, but to the generation of additional spliced transcripts in the absence of the drug (Extended Data Fig h,i) . The original SF3B3-on cassette (hereafter referred to as X on ) was used for all further studies.
Next, we tested X on for responsiveness when expressed from promoters of varying strengths. HEK293 cells were transfected with expression plasmids containing the X on luciferase encoding cassettes under the control of the Rous sarcoma virus (RSV), the phosphoglycerate kinase (PGK), or the minimal cytomegalovirus (mCMV) promoter. All promoters drove inducible expression ( Fig. 4a) , with a clear dose response in foldchange luciferase activity ( Fig. 4b , Extended Data 4a,b) that was mirrored by splicing assessment (Fig. 4c , Extended Data 4c). Overall these constructs provide a gradient of induction with RSV>PGK>mCMV.
To assess the X on system in vivo, an AAV X on vector was developed and packaged into AAV9 (AAV9.RSV.X on .eGFP). AAV9.X on .eGFP (3E11 vg/mouse) was administrated intravenously (IV) to mice, and 4 weeks later animals were given a single dose of vehicle or LMI070 at 5 or 50 mg/kg and eGFP expression assessed 24 h later ( Fig. 5a ).
There was notable eGFP expression in sections from liver (Fig. 5b ). The dose response in eGFP signal noted in tissues by microscopy was confirmed by western blot ( Fig. 5c , Extended Data Fig. 5a ) and splicing assay ( Fig. 5d ). Cumulatively, these data show that in vivo, the X on cassette can be used to drive gene expression from AAV vectors after a single administration of drug. Importantly, protein levels and novel exon splicing directly correlated to the LMI070 dose.
To assess the applicability of our system for brain targeted gene therapies, the X on was packaged into AAVPHPeB 14 (AAVPHPeB.X on .eGFP) and delivered IV to mice (3E11 vg/mouse). Again, eGFP expression and novel exon splicing were evident only in response to drug, and in dose responsive manner (Extended Data Fig 5b,c) .
While gene editing approaches provide an enormous opportunity for altering or removing disease alleles, prolonged expression of the editing machinery from viral vectors could be problematic. The editing enzymes are foreign proteins and may induce immune responses, and prolonged gene expression would increase opportunities for off-target editing 15, 16 . We tested the utility of the X on system to regulate editing, using huntingtin (HTT), a target for gene silencing approaches for Huntington's disease (HD) 17 , as an example.
First, we designed gRNAs to mediate SaCas9-mediated deletion of mutant HTT (mHTT) exon 1. For this, we took advantage of a single nucleotide polymorphism (SNP) 5' to mHTT exon 1 that creates a SaCas9 protospacer adjacent motif (PAM; sg935, Fig. 6a , Extended Data 6a). When used in combination with a sgRNA targeting the downstream intron (sgi3, Fig. 6a , Extended Data 6a) 18 , these gRNAs edit HTT exon1 via SaCas9 and reduce HTT mRNA and protein levels (Extended Data Fig. 6b-e ). Next, the X on switch for drug-inducible SaCas9 expression was generated, and compared to the constitutively active cassette (Fig. 6b ). There was a clear dose response of SaCas9 expression with LMI070 ( Fig. 6c ). X on -SaCas9 plus the relevant gRNAs were then transfected in HEK293 cells and the HTT locus, HTT mRNA and HTT protein levels assessed ( Fig. 6d ). There was equivalent editing between the samples treated with LMI070 and the samples constitutively expressing SaCas9. (Fig. 6e ). More importantly, there was a concomitant reduction at the RNA level upon LMI070 treatment, with HTT transcripts reduced by 50%, similar to the extent noted in cells transfected with the constitutively active editing expression cassette ( Fig. 6f ). Protein levels were similarly reduced ( Fig. 6g ). And while minimal editing was detected on cells transfected with active gRNAs and X on -SaCas9 treated with DMSO ( Fig. 1e ), transcript and protein levels remained unaffected ( Fig. 6f,g) . Together, our data show that the X on switch together with allele specific gRNAs directed to mHTT provides an important advance to HD treatment.
In summary, we present a simple, highly adaptable tool for regulated gene expression for in vitro cell biology applications and in vivo evaluation of any protein and testing of new therapies. We show the utility of the X on system for gene addition and gene editing, and demonstrate its exquisite control in cells in culture, or in tissues via AAV delivery.
Researchers can use X on in cells or animals to test for additional waves of expression, and use different promoters and drug doses for varying levels of inducibility. The X on tool also gives researchers the means to test gene products that when constitutively expressed are toxic. Indeed, the X on system can be applied to any biological question where fine expression control is desired.
Methods
Cell culture, transfection and LMI070/RG7800 treatment: Human embryonic kidney (HEK293) cells (obtained from CHOP Research Vector Core stock) were maintained in DMEM media containing 10% Fetal Bovine Serum (FBS), 1% L-Glutamine and 1% penicillin/streptomycin at 37 °C with 5% CO2. Cells were cultured in 24 well plates and transfected at 80-90% confluence using Lipofectamine 2000 transfection reagent, according to the manufacturer's protocol. For all experiments, 4 hours after plasmid transfection, cells were treated with LMI070 (MedChemExpress, HY-19620, suspended in DMSO) or RG7800 (MedChemExpress, HY-101792A, suspended in H2O) at the indicated concentrations. Cells were tested for mycoplasma by Research Vector Core. None of the cells used in the study were listed in ICLAC database of commonly misidentified cell lines.
Plasmids, primers and custom made TaqMan gene expression assays.
All plasmids, primer sequences, and custom Taqman gene expression assays to determine SF3B3 novel exon inclusion are available upon request. Primers and custom Taqman gene expression assays were obtained from IDT Integrated DNA Technologies.
In vitro luciferase assays HEK293 cells were cultured in DMEM (10% FBS (v/v), 1% Pen/ Strep (v/v), and 1% Lglutamine (v/v) in a 24-well plate. At 70%-80% confluence, cells were co-transfected with the X on . Firefly luciferase cassettes (0.3µg/well) and a SV40p-Renilla luciferase cassette as transfection control (0.02µg/well). Four hours after transfections cells were treated either with LMI070 or RG7800 at indicated concentrations. At 24 h after transfection, cells were rinsed with ice-cold PBS and Renilla and Firefly luciferase activities were assessed using the Dual-Luciferase Reporter Assay System (Promega) according to the manufacturer's instructions. Luminescent readouts were obtained with a Monolight 3010 luminometer (Pharmigen). Relative light units (RLUs) were calculated as the quotient of Renilla/Firefly RLUs and results expressed relative to mock treated control cells.
Animals and Histology
Animal protocols were approved by The Children's Hospital of Philadelphia Institutional Animal Care and Use Committee. Five to six-week-old male C57Bl6/j mice were obtained from Jackson Laboratories (Bar Harbor, ME, USA). AAV vectors (AAV9. X on .eGFP or AAVPHBeB.X on .eGFP; generated at the CHOP Research Vector Core) were administrated by retroorbital injection at 7-8 weeks of age with a total of 3E11 vg in150 µl infused. After 4 weeks, a single dose of LMI070 (5 or 50mg/kg, MedChemExpress HY-19620) or vehicle solution was administrated by oral gavage. After 18-24h, mice used for biochemical or molecular studies were anesthetized and perfused with 0.9% cold saline mixed with 2-ml RNAlater (Ambion) solution. Brains and liver samples were collected, flash frozen in liquid nitrogen, and stored at −80 C until use. For immunohistochemistry studies, mice were perfused with 15 mL ice-cold 0.1M PBS followed by 15 mL 4% paraformaldehyde. For brain sections, eGFP visualization was done by IHC using rabbit anti-GFP antibody (Invitrogen, 1:200) followed by Alexa488-conjugated goat anti-rabbit (Invitrogen, 1:500) and Alexa488-conjugated chicken anti-goat (Invitrogen, 1:500). Slices were mounted on Superfrost plus slides and coverslips mounted using fluoro-gel mounting media. Sections were analyzed using a 
RNA extraction, RT-PCR and Splicing assays
Total RNA was extracted using Trizol (Life Technologies) according to the manufacturer's protocol, with the exception of 1 µL Glycoblue (Life Technologies) in addition to the aqueous phase on the isopropanol precipitation step and a single wash with cold 70% ethanol. To determine HTT expression levels after transfection, RNA samples were quantified by spectrophotometry and subsequently cDNAs generated from 1 mg of total RNA with random hexamers (TaqMan RT reagents, Applied Biosystems). To determine human HTT expression levels in HEK293 cells, we used TaqMan probes for human HTT and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNAs obtained from Applied Biosystems. Relative HTT gene expression was determined using the ddCt method. To determine splicing of the SMN2-on and X on switches, 2 µg of total RNA from HEK293 cells or tissue samples was treated with DNAseI Free kit (Thermofisher) followed by cDNA generation using the High capacity cDNA kit (Thermofisher). Splicing was determined by PCR using the Phusion High-Fidelity polymerase (Thermofisher) and PCR products separated on a 2.5% agarose gel pre-stained with EtBr and spliced-in and spliced-out band densitometry performed using with the ChemiDoc Imaging System (BioRad) and Image Lab analysis software. Splicing induction from mouse tissues was determined using two custom TaqMan assays designed to determine total or LMI070-spliced in mRNA transcripts. The percentage of induction was determined by dividing the average Ct novel exon and average Ct Total, relative to control animals injected with AAV virus plus vehicle.
Western Blots
HEK293 cells were rinsed and lysed with Passive Lysis Buffer (PBL, Promega), protein concentrations determined using the DC protein assay (Bio-Rad), and 10-20 µg of protein loaded on a 3%-8% NuPAGE Tris-Acetate Gel in tris-acetate buffer (Novex Life Technologies) or a 4-12% NuPAGE TrisBis NuPAGE gels in MES buffer (Novex Life Technologies) to determine HTT, SaCas9, or eGFP protein levels, respectively, with bcatenin as loading control. Livers were homogenized in RIPA buffer (final concentration: 50 mM Tris, 150 mM NaCl, 1% Triton-X100, 0.1% SDS, 0.5% sodium deoxycholate, with Complete protease inhibitors (Roche) and samples incubated for 1 hr rotating at 4°C then clarified by centrifugation at 10,000 x g for 10 minutes. Total protein concentration was determined by DC protein assay (BioRad) and 30 µg loaded on a 4-12% NuPAGE Bis-tris gels in MES buffer (Novex Life Technologies) to determine eGFP and b-catenin levels. After electrophoresis, proteins were transferred to 0.2 µm PVDF (Bio-Rad). Membranes were blocked with 5% milk in PBS-T and then blotted with a mouse anti-HTT (MAB2166. dilution: 1:5,000; Millipore), rabbit anti b--catenin (Ab2365. dilution: 1:5,000; Abcam), HA Tag antibody for SaCas9 protein (2-2.2.14, Thermofisher), rabbit anti-GFP (A11122, Invitrogen) followed by horseradish peroxidase-coupled antibodies (Goat anti-mouse: 115-035-146. dilution: 1:10,000 or Goat anti-Rabbit: 111-035-144. dilution: 1:50,000; Jackson ImmunoResearch). Blots were developed with ECL Plus reagents (Amersham Pharmacia) and imaged on the ChemiDoc Imaging System (BioRad).
RNA-Seq Methods
Data from 4 LMI070 treated and 4 DMSO treated HEK293 cell groups were obtained after sequencing across two lanes run on an Illumina Hi-Seq 4000. The resulting fastq files were aligned to the GRCh38 human genome obtained from Ensembl using the STAR aligner. 19 Splice junction output by STAR were quantified using a custom R script designed to identify splicing events unique to LMI070 treatment. Top ranking LMI070exclusive splice events were manually assessed for their applicability to function as a splicing switch. A primary requirement of this evaluation was that two splice events (donor and acceptor) were identified as exclusive or enriched in LMI070 treated cells creating inclusion of a pseudoexon of reasonable size. Candidate splice events were visually evaluated using the Sashimi plot function available in IGV 20, 21 .
To assess the exclusivity of LMI070 induced splice sites to LMI070 treatment we evaluated the frequency with which candidate splice junctions were previously identified in diverse human RNA-Seq datasets deposited in the sequence read archive (SRA). This analysis was performed using Intropolis, a database of exon-exon junctions from 21,504 human RNA-Seq samples in the SRA archive. The Intropolis database is indexed by GRCh37 genomic position so we first converted our GRCh38 positions to GRCh37 using the LiftOver tool from the UCSC genome browser. 22 We then queried LMI070 induced splice sites against the Intropolis database using a custom python script. The results for each LMI070 candidate splice event are summarized in Supplementary table 1. Differential gene expression analysis was performed using DESeq2 to compare samples from the LMI070 and DMSO conditions. 23 To visualize the abundance of meaningfully differentially expressed genes we generated a volcano plot with .05 Benjamini-Hochberg adjusted p-value threshold and a 0.1 log fold change threshold.
Data availability
Custom R and Python scripts will be made available on Github. RNA-Seq datasets will be archived in the NCBI Gene Expression Omnibus (GEO).
Statistical analysis
Statistical analyses were performed using GraphPad Prism v5.0 software. Outlier samples were detected using the Grubb's test (a = 0.05). Normal distribution of the samples was determined by using the D'Agostino and Pearson normality test. Data was analyzed using one-way ANOVA followed by a Bonferroni's post hoc. Statistical significance was considered with a p < 0.05. All results are shown as the mean ± SEM. 
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